Higher Doses of Administered Paricalcitol is Associated with Greater 5-Year Survival in African American Hemodialysis Patients Compared to other Races

Download

Miller J, Ricks J, Streja E, Norris K, Nissenson A, Kovesdy C, Kalantar-Zadeh K. Higher Doses of Administered Paricalcitol is Associated with Greater 5-Year Survival in African American Hemodialysis Patients Compared to other Races. American Society of Nephrology Renal Week. San Diego, CA, Oct 27 – Nov 1, 2009.